GlassScriptPhysician profile
Michael Caruso
NPI 1720267891
$2,754.16
in general payments reported to CMS, 2019-2025
25 companies · $121 in 2025
The $121 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $62.80 · 2022: $725 · 2023: $798 · 2024: $1,047 · 2025: $121.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,966 · Education: $1.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,965.73 |
| Education | $1.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $397.61 | 2022-2025 | |
| Lilly USA, LLC | $314.93 | 2022-2024 | Mounjaro, Jardiance, Trulicity |
| Novo Nordisk INC | $294.44 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $269.11 | 2022-2025 | Farxiga, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $254.11 | 2022-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Amgen INC. | $225.97 | 2022-2025 | Repatha, Otezla, Evenity |
| Sanofi-Aventis U.S. LLC | $212.70 | 2022-2023 | |
| Abbvie INC. | $142.09 | 2023-2024 | Ubrelvy, Mavyret, Qulipta |
| Edwards Lifesciences Corporation | $76.34 | 2022-2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Corcept Therapeutics | $65.89 | 2023-2024 | Korlym |
| Medtronic USA, INC. | $62.80 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $61.26 | 2022-2024 | Ofev, Jardiance |
| Boston Scientific Corporation | $58.80 | 2024 | Wavewriter Alpha Prime 16 |
| Esperion Therapeutics, INC. | $47.50 | 2023-2024 | Nexletol |
| Abbott Laboratories | $39.43 | 2023-2025 | Eterna, Afinion 2 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $39.20 | 2022-2024 | Rexulti |
| Exact Sciences Corporation | $35.91 | 2024 | Cologuard Collection Kit |
| Saluda Medical Americas, INC. | $31.60 | 2024 | Evoke |
| Pfizer INC. | $23.33 | 2023 | |
| Dexcom, INC. | $22.68 | 2025 | Dexcom G6 Transmitter |
| Allergan, INC. | $17.96 | 2022 | |
| Amarin Pharma, INC. | $17.17 | 2022 | |
| Ironwood Pharmaceuticals, INC | $16.50 | 2023 | Linzess |
| Ibsa Pharma INC. | $15.00 | 2024 | Licart, Tirosint |
| E.R. Squibb & Sons, L.L.C. | $11.83 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Caruso listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.